As we have previously described in this review, targeting of CSF-1R with a monoclonal antibody (RG7155) potently inhibited TAM recruitment into the tumor site while increasing the anti-tumor CD8+/CD4+ T cell ratio (Ries et al., 2014). The gene discussed is CSF1R; the disease is neoplasm.